Gilead Sciences (GILD) ended the recent trading session at $149.45, demonstrating a -1.21% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.25%. Elsewhere, the Dow lost 0.86%, while the tech-heavy Nasdaq added 0.24%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 0.91% in the past month. In that same time, the Medical sector lost 1.01%, while the S&P 500 lost 0.42%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $2.15, reflecting a 12.96% decrease from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $7.79 billion, indicating a 0.3% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.48 per share and a revenue of $30.74 billion, signifying shifts of -105.89% and +4.4%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.2% lower. Right now, Gilead Sciences possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 180, which puts it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).